EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
ca.investing.com on MSN10h
Moderna has limited upside: Barclays
Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...
Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...